Navigating Decisions in a New Treatment Era in HCC: Current Evidence, Key Trials, and Future Frontiers

In this online program based on a dynamic CCO symposium from the 2020 ASCO GI Symposium experts discuss evidence-based best practices in treating patients with HCC. Watch the on-demand Webcast and download the slides now.

Share

Program Content

Activities

First-line Therapy
Selection of First-line Therapy in Advanced, Unresectable HCC
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: January 23, 2020

Expires: January 21, 2021

Incorporating Immunotherapy
Incorporating Immune Checkpoint Inhibitors Into Treatment For Patients With HCC
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: January 23, 2020

Expires: January 21, 2021

Targeted Second-Line Therapy
Targeted Therapy Options in the Second-line Setting for Patients With Advanced HCC
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: January 23, 2020

Expires: January 21, 2021

Faculty

cover img faculity

James M Cleary, MD, PhD

Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

cover img faculity

Stacey Stein, MD

Assistant Professor of Medicine
Yale University School of Medicine
Section of Medical Oncology
New Haven, Connecticut

cover img faculity

Andrew X. Zhu, MD, PhD, FACP

Director, Liver Cancer Research
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Provided by

ProCE Banner

Supporters

Supported by educational grants from

Eisai

Merck Sharp & Dohme Corp.